Literature DB >> 29048619

MicroRNA-381 serves as a prognostic factor and inhibits migration and invasion in non-small cell lung cancer by targeting LRH-1.

Chunyan Tian1, Jun Li2, Lili Ren3, Ren Peng1, Binbin Chen1, Yumei Lin2.   

Abstract

Accumulating evidence has demonstrated that aberrant miRNAs were involved in carcinogenesis and tumor progression by regulating oncogenes or tumor suppressor expression. Dysregulation of miR-381 has been reported in different tumors. However, the clinical roles and underlying mechanism in non-small cell lung cancer (NSCLC) remains to be elucidated. We found the expression of miR-381 was significantly downregulated in both NSCLC tissues and cell lines. Clinical analysis revealed the reduced miR-381 was obviously associated with advanced TNM stage and lymph node metastasis. Moreover, we disclosed that miR-381 was a novel independent prognostic marker for predicting 5-year survival of NSCLC patients. The ectopic overexpression of miR-381 inhibited cell migration and invasion in vitro and in vivo. Notably, miR-381 could modulate LRH-1 by directly binding to its 3'-UTR. In clinical samples of NSCLC, miR-381 inversely correlated with LRH-1 expression, which performed positive roles in NSCLC migration and invasion. Alteration of LRH-1 expression at least partially abolished the migration and invasion of miR-381 on NSCLC cells. Here, we identified LRH-1 as a functional target of miR-381 in NSCLC. In conclusion, our data indicated that miR-381 inhibited migration and invasion of NSCLC by targeting LRH-1, and may represent a novel potential therapeutic target and prognostic marker for NSCLC.

Entities:  

Mesh:

Substances:

Year:  2017        PMID: 29048619     DOI: 10.3892/or.2017.5956

Source DB:  PubMed          Journal:  Oncol Rep        ISSN: 1021-335X            Impact factor:   3.906


  8 in total

1.  SNHG15 Contributes To Cisplatin Resistance In Breast Cancer Through Sponging miR-381.

Authors:  Hailong Mi; Xiaochun Wang; Fang Wang; Lin Li; Mingzhi Zhu; Nan Wang; Youyi Xiong; Yuanting Gu
Journal:  Onco Targets Ther       Date:  2020-01-21       Impact factor: 4.147

2.  EZH2 Contributes To Cisplatin Resistance In Breast Cancer By Epigenetically Suppressing miR-381 Expression.

Authors:  Dongwei Dou; Xin Ge; Xinxing Wang; Xiaodong Xu; Zhe Zhang; Jingjing Seng; Zhang Cao; Yuanting Gu; Mingli Han
Journal:  Onco Targets Ther       Date:  2019-11-13       Impact factor: 4.147

Review 3.  MicroRNA-381-A Key Transcriptional Regulator: Its Biological Function and Clinical Application Prospects in Cancer.

Authors:  Xue Zeng; Zhe Cao; Wenhao Luo; Lianfang Zheng; Taiping Zhang
Journal:  Front Oncol       Date:  2020-11-26       Impact factor: 6.244

4.  LncRNA SNHG1 promotes tumor progression and cisplatin resistance through epigenetically silencing miR-381 in breast cancer.

Authors:  Mingkun Zhang; Liu Yang; Lan Hou; Xueyuan Tang
Journal:  Bioengineered       Date:  2021-12       Impact factor: 3.269

5.  CPNE1 is a potential prognostic biomarker, associated with immune infiltrates and promotes progression of hepatocellular carcinoma.

Authors:  Jinfang Su; Yongbiao Huang; Yali Wang; Rui Li; Wanjun Deng; Hao Zhang; Huihua Xiong
Journal:  Cancer Cell Int       Date:  2022-02-09       Impact factor: 5.722

Review 6.  MicroRNA-381 in human cancer: Its involvement in tumour biology and clinical applications potential.

Authors:  Huanhuan Sha; Yujie Gan; Feng Xu; Yue Zhu; Renrui Zou; Weiwei Peng; Zhiya Wu; Rong Ma; Jianzhong Wu; Jifeng Feng
Journal:  J Cell Mol Med       Date:  2022-01-11       Impact factor: 5.310

7.  Clinical significance of dysregulation of miR-381 in pediatric acute myeloid leukemia.

Authors:  Piqiang Zhang; Deyun Sun; Xuemei Sun; Hongjuan Li
Journal:  Eur J Med Res       Date:  2020-09-16       Impact factor: 2.175

8.  miR-381-3p suppresses breast cancer progression by inhibition of epithelial-mesenchymal transition.

Authors:  Yong-Zheng Yu; Qiang Mu; Qian Ren; Li-Juan Xie; Qi-Tang Wang; Cui-Ping Wang
Journal:  World J Surg Oncol       Date:  2021-08-06       Impact factor: 2.754

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.